Corbus Pharmaceuticals reported that its oral CB1 inverse agonist CRB-913 produced a 5.0% mean weight loss at 12 weeks on the highest 60 mg dose in the CANYON-1 Phase 1b trial, with every participant in that cohort who completed the study losing at least some weight and 44.4% losing 5% or more from baseline. Those numbers matter because they come from a 254-person, placebo-controlled, 16-week study (with 12 weeks of active dosing), not a small open-label run, and all three doses cleared statistical significance against placebo at p less than 0.0001.

The discontinuation rate due to adverse events was 8.3% across all cohorts, a figure Corbus directly benchmarks against published GLP-1 agonist data. The psychiatric safety signal, often the central concern for CB1 inverse agonists given the class history, stayed quiet: no severe psychiatric treatment-emergent adverse events appeared in any cohort, and the events that did occur were mostly mild and resolved. That psychiatric profile will be the number to pressure-test in Phase 2, since earlier CB1 blockers failed on exactly this point.

The 5% weight loss at 12 weeks on 60 mg is a reasonable early read, though semaglutide 2.4 mg reaches roughly 6% by week 12 in STEP trial data. CRB-913’s dose-response curve showed no plateau at 60 mg, which Corbus highlights as a reason to expect more at higher doses or longer duration. The waist circumference reduction of 3.94 cm and BMI change of nearly 5% in the 60 mg cohort track in the same direction, adding metabolic breadth to what is otherwise still early efficacy data.

What the CANYON-1 poster does not resolve is how CRB-913 performs beyond 12 weeks. Participants were dosed for 12 weeks and then followed for four more without treatment, so durability data are absent. The next concrete marker to watch is whether Corbus announces a Phase 2 design that extends treatment duration and tests doses above 60 mg, the two gaps this dataset leaves plainly open.

Source link: https://www.sec.gov/Archives/edgar/data/1595097/000119312526462186/crbp-20261116.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.